CN101204532A - Medicine for prostate disease and preparation method thereof - Google Patents
Medicine for prostate disease and preparation method thereof Download PDFInfo
- Publication number
- CN101204532A CN101204532A CNA2007101158031A CN200710115803A CN101204532A CN 101204532 A CN101204532 A CN 101204532A CN A2007101158031 A CNA2007101158031 A CN A2007101158031A CN 200710115803 A CN200710115803 A CN 200710115803A CN 101204532 A CN101204532 A CN 101204532A
- Authority
- CN
- China
- Prior art keywords
- grams
- medicine
- root
- actinolitum
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating prostate and a preparation method thereof.The medicine for treating prostatitis of the invention is prepared by the following materials: 10g of tall gastrodis tuber, 10g of ginger pinellia, 5g of astragalus root, 3g of garden burnet root, 5g of psoralea root, 5g of purslane speedwell, 10g of jujube seed, 5g of dahurian angelica and 5g of actinolitum. The method of the invention for preparing the medicine used for treating the prostatitis comprises the following steps that: crude drug of tall gastrodis tuber, ginger pinellia, astragalus root, garden burnet root, psoralea root, purslane speedwell, jujube seed, dahurian angelica and actinolitum are scaled to be pulverized into powder; 50g of honey is boiled; the drug is poured into the boiled honey to be stirred evenly; pills are made by dividing weight.The invention has the advantages of dramatic healing efficacy of clinical application, distinguishing drug potency, good drug property, treatment of both manifestation and root cause of disease, security and reliability, oral taking without provocation to internal organs, widely application, economical and practical, wide medicinal herb resource, small side effect, little toxicity, convenient usage, easy to carry, manufacture, transport and store, as well as wide market prospect.
Description
(1) technical field
The present invention relates to medical technical field, prostatic medicine of particularly a kind of treatment and preparation method thereof.
(2) background technology
Prostatosis is a kind of male's commonly encountered diseases, frequently-occurring disease, comprises prostatitis, prostatic hyperplasia hypertrophy and carcinoma of prostate clinically.Cardinal symptom: the patient is with frequent micturition or the urine meaning is always arranged, slight dysurea, and urethral orifice pain, the urethra idol has overflows white mucus; Hypogastric region dull pain; Pudendum or testicular pain or sense of discomfort, the perineum damp, sexual function is unusual.
At present, various big hospital treatment prostate is based on oral drugs and operation, and these Therapeutic Method have certain curative effect, but operative treatment can cause the injury of the spirit and the human body to the patient, and oral drugs are difficult to thoroughly eradicate prostatosis.
(3) summary of the invention
The object of the invention is to provide a kind of determined curative effect, the prostatic medicine of the treatment of nontoxic pair of effect.
Another object of the present invention is to provide the preparation method of this medicine.
The prostatitic medicine of treatment of the present invention is characterized in that: made by following raw material: Rhizoma Gastrodiae 10 grams, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10 grams, the Radix Astragali 5 grams, Radix Sanguisorbae 3 grams, Fructus Psoraleae 5 grams, purslane speedwell Herba 5 grams, Semen Ziziphi Spinosae 10 grams, the Radix Angelicae Dahuricae 5 grams, Actinolitum 5 grams.
The present invention cures mainly indication: acute and chronic prostatitis, prostatic hyperplasia, seminal vesiculitis, acute urinary retention, carcinoma of prostate all have significant curative effect, have treatment preferably to alleviate the effect that suppresses rehabilitation.
Function: blood circulation promoting and blood stasis dispelling, dredge smart road, clearing away heat-damp and promoting diuresis, promoting blood circulation, clear hard eliminating stagnation, eliminate edema, improve the convoluted tubule of testis function, the concentration of androgen and cholesterol increases sexual organ's flow in the reduction blood, and sexual function improving promotes the gonad secretion.
Instructions of taking and consumption: become human oral, every 9 gram of pill, taking 6 pairs is a course of treatment, after twice of every days, a ball serve on 3 pairs, the 4th pair ball every day one, the 5th secondary two days one balls, the 6th secondary three days one balls.Taking medicine before meal usefulness, can cure obstinate case general 1-3 course of treatment, can continue to take and consolidate curative effect in case recurrence.
Points for attention: avoid clothes wine during the medication.
The preparation method of the prostatitic medicine of treatment of the present invention is characterized in that: may further comprise the steps:
1) takes by weighing each raw material Chinese medicine Rhizoma Gastrodiae, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), the Radix Astragali, Radix Sanguisorbae, Fructus Psoraleae, purslane speedwell Herba, Semen Ziziphi Spinosae, the Radix Angelicae Dahuricae and Actinolitum, it is ground into powder;
2) getting 50 gram Mel boils;
3) medicine is poured in the Mel after boiling and stirred;
4) component is made pill.
Beneficial effect of the present invention: clinical practice is evident in efficacy, the drug effect uniqueness, and the property of medicine is bringd into play, treating both the principal and secondary aspects of a disease, safe and reliable, the internal organs that do not stimulate for oral administration, indication is wide, and is economical and practical, and the medicine source is wide, dosage is little, side effect is little, and toxicity is little, and easy to use, easy to carry, convenient for production, convenient transportation, storage are convenient, no obvious toxic-side effects, market prospect is wide.
(4) specific embodiment
1 one kinds of prostatic medicines of treatment of embodiment are made by following raw material: Rhizoma Gastrodiae 10 grams, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10 grams, the Radix Astragali 5 grams, Radix Sanguisorbae 3 grams, Fructus Psoraleae 5 grams, purslane speedwell Herba 5 grams, Semen Ziziphi Spinosae 10 grams, the Radix Angelicae Dahuricae 5 grams, Actinolitum 5 grams.
The preparation method of described medicine may further comprise the steps:
1. take by weighing each raw material Chinese medicine Rhizoma Gastrodiae, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), the Radix Astragali, Radix Sanguisorbae, Fructus Psoraleae, purslane speedwell Herba, Semen Ziziphi Spinosae, the Radix Angelicae Dahuricae and Actinolitum, it is ground into powder;
2. getting 50 gram Mel boils;
3. medicine is poured in the Mel after boiling and stirred;
4. component is made pill.
Data is summed up in clinical research:
1 prescription source and mechanism:
The present invention is through exploring for many years, long-term accumulation, personal practice, existing indivedual (suiting the medicine to the illness) hold concurrently again certain universality (to disease) thereby a kind of or a class disease embodied obvious and stable conditioning repairing and treating rehabilitation is arranged.Chinese medicine only relies on single medicinal material and looks after not comprehensively, so multiple medicine suitably must be cooperated, utilizes mutual collaborative or resistant function, raising curative effect and reduce untoward reaction.
2 clinical observations
(1) physical data
The inventor carries out clinical observation treatment to 100 routine patients so far since nineteen eighty-two, prostatitis 50 examples wherein, and prostatitis merges urethritis 11 examples, prostatic hyperplasia 24 examples, other (seminal vesiculitis, acute urinary retention) 25 examples.
(2) efficacy assessment standard
" healing ": the clinical symptoms sign disappears, and it is normal that functional activity recovers.
" produce effects ": the basic or big portion of clinical symptoms sign disappears.
" effectively ": clinical symptoms is clearly better or takes a turn for the better.
" invalid ": the clinical symptoms sign does not have improvement.
(4) therapeutic effect:
Clinical cure 72 examples account for 72%; Produce effects 19 examples account for 19%; Effective 9 examples account for 9%; Invalid 0 example, total effective rate 100%.Good effect,
3 clinical verifications are given an example:
(1) prostatitis: Liu * *, 40 years old, the man suffered from prostatitis, and it is invalid to obey multiple medicine, takes medicine of the present invention, two courses of treatment, cures fully.
(2) prostatic hyperplasia: open * *, the man, 60 years old, prostatic hyperplasia, it is invalid to take medicines such as " QIANLIEKANG ", takes medicine of the present invention, three recoveries from illness course of treatment, not recurrence in several years so far.
(3) seminal vesiculitis: merchant * *, the man, 25 years old, seminal vesiculitis, it is invalid to take a large amount of Chinese medicines and medicines such as " prostate diseases ", takes recovery from illness course of treatment of the present invention, and it is normal that ultrasound diagnosis recovers.
Claims (2)
1. the prostatic medicine of treatment is characterized in that: made by following raw material: Rhizoma Gastrodiae 10 grams, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10 grams, the Radix Astragali 5 grams, Radix Sanguisorbae 3 grams, Fructus Psoraleae 5 grams, purslane speedwell Herba 5 grams, Semen Ziziphi Spinosae 10 grams, the Radix Angelicae Dahuricae 5 grams, Actinolitum 5 grams.
2. the preparation method of the described medicine of claim 1 is characterized in that: may further comprise the steps:
1) takes by weighing each raw material Chinese medicine Rhizoma Gastrodiae, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), the Radix Astragali, Radix Sanguisorbae, Fructus Psoraleae, purslane speedwell Herba, Semen Ziziphi Spinosae, the Radix Angelicae Dahuricae and Actinolitum, it is ground into powder;
2) getting 50 gram Mel boils;
3) medicine is poured in the Mel after boiling and stirred;
4) component is made pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101158031A CN101204532B (en) | 2007-12-19 | 2007-12-19 | Medicine for prostate disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101158031A CN101204532B (en) | 2007-12-19 | 2007-12-19 | Medicine for prostate disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101204532A true CN101204532A (en) | 2008-06-25 |
| CN101204532B CN101204532B (en) | 2010-08-11 |
Family
ID=39565161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101158031A Expired - Fee Related CN101204532B (en) | 2007-12-19 | 2007-12-19 | Medicine for prostate disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101204532B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526509A (en) * | 2012-01-31 | 2012-07-04 | 孙义岭 | Medicine for treating hepatomegaly |
| CN102579897A (en) * | 2012-02-28 | 2012-07-18 | 朱志红 | Medicine for treating postoperative uroschesis of anorectal diseases and preparation method thereof |
| CN104523766A (en) * | 2012-06-27 | 2015-04-22 | 景鑫生物科技有限公司 | Extract of Stachys sieboldii |
| CN108311155A (en) * | 2018-05-14 | 2018-07-24 | 邢月军 | A method of catalysis prepares treatment prostate cancer disease drug A Palu amine intermediates |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305505C (en) * | 2005-10-17 | 2007-03-21 | 高春 | Medicament for treating prostatauxe inflammation |
-
2007
- 2007-12-19 CN CN2007101158031A patent/CN101204532B/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526509A (en) * | 2012-01-31 | 2012-07-04 | 孙义岭 | Medicine for treating hepatomegaly |
| CN102526509B (en) * | 2012-01-31 | 2013-12-04 | 孙义岭 | Medicine for treating hepatomegaly |
| CN102579897A (en) * | 2012-02-28 | 2012-07-18 | 朱志红 | Medicine for treating postoperative uroschesis of anorectal diseases and preparation method thereof |
| CN104523766A (en) * | 2012-06-27 | 2015-04-22 | 景鑫生物科技有限公司 | Extract of Stachys sieboldii |
| CN108311155A (en) * | 2018-05-14 | 2018-07-24 | 邢月军 | A method of catalysis prepares treatment prostate cancer disease drug A Palu amine intermediates |
| CN108311155B (en) * | 2018-05-14 | 2020-11-06 | 上海奥萝拉医药科技有限公司 | Method for catalytically preparing apalumide intermediate serving as medicine for treating prostate cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101204532B (en) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101843699B (en) | Chinese medicament for treating benign prostatic hyperplasiabrain | |
| CN101843787B (en) | Chinese medicament for treating benign prostatic hyperplasiabrain | |
| CN101234188B (en) | Pharmaceutical composition for treating pain and preparation thereof | |
| CN102228603B (en) | Chinese medicine for treating retention of urine | |
| CN102091295A (en) | Chinese medicinal composition for treating femoral head necrosis and preparation method thereof | |
| CN103341064A (en) | Chinese medicine composition for treating urine retention | |
| CN101204532B (en) | Medicine for prostate disease and preparation method thereof | |
| CN108969642A (en) | A kind of Chinese medicine compound prescription external preparation that treating chronic prostatitis and its preparation process | |
| CN101791385A (en) | Medicine for treating psoriasis | |
| CN101897879A (en) | Traditional Chinese medicine for treating rheumatic arthritis | |
| CN102600351B (en) | Traditional Chinese medicine for treating pruritus cutanea | |
| CN102743717A (en) | Traditional Chinese medicine capsule for treating uterine prolapse | |
| CN100509025C (en) | A medicine for treating diabetes | |
| CN101623455B (en) | Medicine for treating prostate hyperplasia | |
| CN101623387B (en) | Pill for treating traumatic injury, new and old fracture and lumbar muscle strain | |
| CN103301305A (en) | Traditional Chinese medicine for treating prostatic hyperplasia | |
| CN101953937A (en) | Chinese medicament for treating chronic prostatitis | |
| CN101417023B (en) | Traditional Chinese medicine for treating lumbar hyperosteogen and preparation thereof | |
| CN101804179B (en) | Traditional Chinese medicine composition for treating hyperosteogeny of cervical vertebra and lumbar vertebra and preparation method thereof | |
| CN1899564B (en) | External use medicine for treating hyperosteogeny and protrusion of intervertebral disc | |
| CN102228643A (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN103212013A (en) | Chinese medicinal composition for treating epigastric pain | |
| CN101961416A (en) | Traditional Chinese medicine for treating chronic prostatitis | |
| CN101972426A (en) | Traditional Chinese medicine for treating chronic prostatitis | |
| CN101732584B (en) | Throat disinhibiting bagged soaking preparation for treating pharyngitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100811 Termination date: 20131219 |